Techcyte, a leader in AI-powered digital pathology, and Aiforia, a pioneering provider of deep-learning AI solutions for pathology, today announced a strategic partnership to accelerate the adoption of AI-driven workflows in anatomic pathology laboratories worldwide.
This relationship brings together Techcyte’s Fusion Digital Pathology Platform and Aiforia’s AI-powered diagnostic algorithms, beginning with the successful integration of Aiforia’s breast cancer suite into the pathology workflow on Fusion. This real-world application demonstrates the potential of AI-enhanced diagnostics to improve efficiency, accuracy, and patient outcomes.
“Pathology labs struggle to get AI integrated into clinical workflows—they need integrated, intelligent workflows that enhance diagnostic precision and efficiency,” said Tiffany Chen, Chief Medical Officer of Techcyte. “One of Fusion’s core strengths is its ability to enable comprehensive integration of third-party AI algorithms into the platform. By working with Aiforia, we’re ensuring that pathologists can seamlessly access powerful AI tools within Fusion, allowing them to make faster, with the goal of ultimately improving patient care.”
Through this non-exclusive collaboration, Techcyte and Aiforia are jointly working to deliver fully integrated, AI-powered digital pathology workflows to laboratories worldwide. With a focus on full integration, this partnership removes technical barriers that have historically slowed AI adoption in pathology, ensuring that AI-driven insights can be seamlessly incorporated into routine workflows.
“Aiforia’s mission has always been to leverage AI to enhance diagnostic accuracy and efficiency in pathology,” said Jukka Tapaninen, CEO of Aiforia. “By integrating our AI into Techcyte’s Fusion platform, we’re ensuring that labs can harness AI-driven insights in a digital workflow. This relationship represents an important step toward making AI a seamless, everyday tool for pathologists worldwide.”
The successful Fusion-Aiforia integration marks a significant milestone in AI-powered diagnostics, demonstrating the practical application of AI in a real-world clinical setting. By enabling comprehensive integration of third-party AI, Fusion aims to ensure that pathologists can deploy and utilize AI-driven diagnostics with ease, speed, and confidence. With an expanding portfolio of AI applications, this partnership will continue to drive innovation in digital pathology, cancer diagnostics, and beyond.
